Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

por Herbertz, Stephan, Sawyer, J Scott, Stauber, Anja J, Gueorguieva, Ivelina, Driscoll, Kyla E, Estrem, Shawn T, Cleverly, Ann L, Desaiah, Durisala, Guba, Susan C, Benhadji, Karim A, Slapak, Christopher A, Lahn, Michael M
Publicado 2015

Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer

por Huang, Huocong, Zhang, Yuqing, Gallegos, Valerie, Sorrelle, Noah, Zaid, Mohamed Medhat, Toombs, Jason, Du, Wenting, Wright, Steven, Hagopian, Moriah, Wang, Zhaoning, Hosein, Abdel Nasser, Sathe, Adwait Amod, Xing, Chao, Koay, Eugene J, Driscoll, Kyla E, Brekken, Rolf A
Publicado 2019

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combinat...

por Holmgaard, Rikke B., Schaer, David A., Li, Yanxia, Castaneda, Stephen P., Murphy, Mary Y., Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R., Iversen, Philip W., Surguladze, David, Hall, Gerald E., Novosiadly, Ruslan D., Benhadji, Karim A., Plowman, Gregory D., Kalos, Michael, Driscoll, Kyla E.
Publicado 2018

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

por Yingling, Jonathan M., McMillen, William T., Yan, Lei, Huang, Huocong, Sawyer, J. Scott, Graff, Jeremy, Clawson, David K., Britt, Karen S., Anderson, Bryan D., Beight, Douglas W., Desaiah, Durisala, Lahn, Michael M., Benhadji, Karim A., Lallena, Maria J., Holmgaard, Rikke B., Xu, Xiaohong, Zhang, Faming, Manro, Jason R., Iversen, Philip W., Iyer, Chandrasekar V., Brekken, Rolf A., Kalos, Michael D., Driscoll, Kyla E.
Publicado 2017